Search Results - "Mo, May"

Tezepelumab in Adults with Uncontrolled Asthma by Corren, Jonathan, Parnes, Jane R, Wang, Liangwei, Mo, May, Roseti, Stephanie L, Griffiths, Janet M, van der Merwe, René

“…Treatment with tezepelumab, a human monoclonal antibody specific for thymic stromal lymphopoietin, reduced exacerbation frequency among patients whose asthma…”
Get full text

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial by Simpson, Eric L., Parnes, Jane R., She, Dewei, Crouch, Sarah, Rees, William, Mo, May, van der Merwe, René

“…Tezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody, targets thymic stromal lymphopoietin, a cytokine that is implicated in the pathogenesis…”
Get full text

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma by Menzies-Gow, Andrew, Colice, Gene, Griffiths, Janet M, Almqvist, Gun, Ponnarambil, Sandhia, Kaur, Primal, Ruberto, Gennaro, Bowen, Karin, Hellqvist, Åsa, Mo, May, Garcia Gil, Esther

“…Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide…”
Get full text

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma by Wechsler, Michael E, Colice, Gene, Griffiths, Janet M, Almqvist, Gun, Skärby, Tor, Piechowiak, Teresa, Kaur, Primal, Bowen, Karin, Hellqvist, Ãsa, Mo, May, Garcia Gil, Esther

“…Abstract Background Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial…”
Get full text

Improved Discriminative Object Localization Algorithm for Safety Management of Indoor Construction by Hwang, Jungeun, Lee, Kanghyeok, Ei Zan, May Mo, Jang, Minseo, Shin, Do Hyoung

“…Object localization is a sub-field of computer vision-based object recognition technology that identifies object classes and locations. Studies on safety…”
Get full text

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis by Warady, Bradley A., Ng, Eric, Bloss, Laura, Mo, May, Schaefer, Franz, Bacchetta, Justine

“…Background Secondary hyperparathyroidism (sHPT), a complication of chronic kidney disease (CKD) characterized by persistently elevated parathyroid hormone…”
Get full text

Considerations in testing treatment effects on transient event driven health status changes measured by patient reported outcomes by Liu, Jingyuan, Legg, Jason C., Mo, May, Zhang, Xuwen

“…Many treatments and drugs are intended to reduce the occurrence of negative events of interest, control the severity of the events, accelerate recovery from…”
Get full text

Network meta‐regression for ordinal outcomes: Applications in comparing Crohn's disease treatments by Gwon, Yeongjin, Mo, May, Chen, Ming‐Hui, Chi, Zhiyi, Li, Juan, Xia, Amy H., Ibrahim, Joseph G.

“…Crohn's disease (CD) is a life‐long condition associated with recurrent relapses characterized by abdominal pain, weight loss, anemia, and persistent diarrhea…”
Get full text

Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study by LE, Quynh-Thu, KIM, Harold E, BERGER, Dietmar, LIZAMBRI, Richard, HENKE, Michael, SCHNEIDER, Charles J, MURAKÖZY, Györgyi, SKLADOWSKI, Krzysztof, REINISCH, Sabine, CHEN, Yuhchyau, HICKEY, Michael, MO, May, CHEN, Mon-Gy

“…Oral mucositis (OM) is a debilitating toxicity of chemoradiotherapy for head and neck cancer (HNC). This randomized, placebo-controlled, double-blind study…”
Get full text

Improving resource utilisation in SLE drug development through innovative trial design by Garces, Sandra, Karis, Elaine, Merrill, Joan T, Askanase, Anca D, Kalunian, Kenneth, Mo, May, Milmont, Cassandra E

“…SLE is a complex autoimmune disease with considerable unmet need. Numerous clinical trials designed to investigate novel therapies are actively enrolling…”
Get full text

Tezepelumab demonstrates clinically meaningful improvements in asthma control (ACQ-6) in patients with uncontrolled asthma: results from a phase 2b clinical trial by Corren, Jonathan, Parnes, Jane R., Wang, Liangwei, Mo, May, Roseti, Stephanie L., Griffiths, Janet M., O'Quinn, Sean, van der Merwe, Rene

“…Methods This 52-week, randomized, double-blind, placebo-controlled study (NCT02054130) included patients with severe, uncontrolled asthma (Asthma Control…”
Get full text

Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism by Basu, Cynthia, Ma, Xiaoye, Mo, May, Xia, Hong Amy, Brundage, Richard, Al‐Kofahi, Mahmoud, Carlin, Bradley P.

“…Summary In most drug development settings, the regulatory approval process is accompanied by extensive studies performed to understand the drug's…”
Get full text

A case for including spirituality in quality of life measurement in oncology by Brady, Marianne J., Peterman, Amy H., Fitchett, George, Mo, May, Cella, David

“…Most of the commonly used quality of life (QOL) instruments in oncology do not include spirituality as a core domain. However, previous research suggests that…”
Get full text

Rejoinder to the discussion on "LEAP: the latent exchangeability prior for borrowing information from historical data" by Alt, Ethan M, Chang, Xiuya, Jiang, Xun, Liu, Qing, Mo, May, Xia, Hong Amy, Ibrahim, Joseph G

“…The discussions of our paper provide insights into the practical considerations of the latent exchangeability prior while also highlighting further extensions…”
Get full text

LEAP: the latent exchangeability prior for borrowing information from historical data by Alt, Ethan M, Chang, Xiuya, Jiang, Xun, Liu, Qing, Mo, May, Xia, Hong Amy, Ibrahim, Joseph G

“…It is becoming increasingly popular to elicit informative priors on the basis of historical data. Popular existing priors, including the power prior,…”
Get full text

Retrospective Analysis of Relative Dose Intensity in Patients With Non-Hodgkin Lymphoma Receiving CHOP-based Chemotherapy and Pegfilgrastim by BALDUCCI, Lodovico, MO, May, ABELLA, Esteban, SAVEN, Alan

“…To evaluate primary prophylaxis with pegfilgrastim, a recombinant human granulocyte colony-stimulating factor, on maintaining relative dose intensity (RDI) in…”
Get full text

Su1924 - Efficacy and Safety of Abrilumab (AMG 181/MEDI 7183) Therapy for Moderate to Severe Crohn’s Disease by Sandborn, William J., Cyrille, Marcoli, Hansen, Mark Berner, Feagan, Brian G., Loftus, Edward V., Vermeire, Severine, Cruz, Martha L, Mo, May, Sullivan, Barbara A., Reinisch, Walter

Get full text

Evaluation of Relative Dose Intensity (RDI) by Age in Patients (pts) with Non-Hodgkin Lymphoma (NHL) Receiving Pegfilgrastim and CHOP Based Chemotherapy by Balducci, Lodovico, Mo, May, Abella, Steve, Saven, Alan

“…Abstract 4880 The standard of care for aggressive NHL is treatment (tx) with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with rituximab…”
Get full text

Efficacy and Safety of Abrilumab (AMG 181/MEDI 7183) Therapy for Moderate to Severe Crohn’s Disease by Sandborn, William J, Cyrille, Marcoli, Hansen, Mark Berner, Feagan, Brian G, Loftus, Edward V, Vermeire, Severine, Cruz, Martha L, Mo, May, Sullivan, Barbara A, Reinisch, Walter

Get full text

A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy by Hecht, J. Randolph, Pillai, Madhavan, Gollard, Russell, Heim, William, Swan, Forrest, Patel, Ravi, Dreiling, Lyndah, Mo, May, Malik, Imtiaz

“…Abstract Background Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal…”
Get full text